Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-00217830 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A2 | EXPERIMENTAL | - |
| A5 | PLACEBO_COMPARATOR | - |
| A4 | ACTIVE_COMPARATOR | - |
| A3 | EXPERIMENTAL | - |
| A1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-00217830 | DRUG | PF-00217830 5 mg, oral capsule, once daily for 21 days |
| Placebo | OTHER | Placebo, oral capsule, once daily for 21 days |
| Aripiprazole | DRUG | Aripiprazole 15 mg, oral capsule, once daily for 21 days |
Inclusion Criteria: Key inclusion criteria include: * Have a current diagnosis of schizophrenia. * Increase in symptoms over the past 2-4 weeks. * Willing to remain inpatients for the duration of the trial. Exclusion Criteria: * Subjects with a current DSM-IV axis I diagnosis other than schizoph...
Top 15 of 16 competitors
PF-00217830 was studied for the treatment of schizophrenia, specifically for acute exacerbation of the condition. It is an investigational small molecule that was developed by Pfizer as a potential antipsychotic therapy. The compound was evaluated in a Phase 2 clinical trial but has not been approved for any indication.
PF-00217830 targets the dopamine D2 receptor, also known as DRD2. It acts as a partial agonist at this receptor. This mechanism is intended to modulate dopamine signaling, which is implicated in schizophrenia. The target class is a partial agonist, distinguishing it from full antagonists or agonists.
PF-00217830 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. Pfizer is the sponsor of the clinical program for this compound. The drug remains an investigational asset in Pfizer's pipeline.
PF-00217830 is in Phase 2 clinical development. It has completed one Phase 2 trial but has not advanced to Phase 3. The drug is investigational and has not received FDA approval for any indication.
PF-00217830 has been studied in one completed Phase 2 clinical trial, NCT00580125. This trial was a dose-response study evaluating the safety, efficacy, and pharmacokinetics of PF-00217830 compared with placebo in patients with acute exacerbation of schizophrenia. It enrolled 164 participants across the United States, India, Russia, and Ukraine.